Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new stake in shares of Avid Bioservices, Inc. (NASDAQ:CDMO – Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 25,000 shares of the biopharmaceutical company’s stock, valued at approximately $309,000.
A number of other hedge funds and other institutional investors have also bought and sold shares of CDMO. Alpine Associates Management Inc. bought a new position in shares of Avid Bioservices during the 4th quarter valued at approximately $24,034,000. Point72 Asset Management L.P. lifted its holdings in Avid Bioservices by 42.8% during the third quarter. Point72 Asset Management L.P. now owns 3,815,806 shares of the biopharmaceutical company’s stock valued at $43,424,000 after purchasing an additional 1,142,756 shares in the last quarter. Jennison Associates LLC bought a new position in shares of Avid Bioservices in the fourth quarter worth approximately $13,796,000. Point72 DIFC Ltd boosted its position in shares of Avid Bioservices by 12,530.9% in the third quarter. Point72 DIFC Ltd now owns 1,003,653 shares of the biopharmaceutical company’s stock worth $11,422,000 after purchasing an additional 995,707 shares during the period. Finally, Alberta Investment Management Corp purchased a new stake in shares of Avid Bioservices in the fourth quarter worth $8,028,000. Hedge funds and other institutional investors own 97.16% of the company’s stock.
Insider Buying and Selling at Avid Bioservices
In other Avid Bioservices news, insider Richard A. Richieri sold 2,283 shares of the stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $12.37, for a total transaction of $28,240.71. Following the completion of the transaction, the insider now owns 49,535 shares of the company’s stock, valued at $612,747.95. This represents a 4.41 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 3.05% of the company’s stock.
Avid Bioservices Stock Up 0.1 %
Analysts Set New Price Targets
Separately, Stephens cut shares of Avid Bioservices from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, December 4th. One investment analyst has rated the stock with a sell rating and four have assigned a hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $12.25.
Read Our Latest Report on Avid Bioservices
Avid Bioservices Company Profile
Avid Bioservices, Inc operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization services.
Featured Stories
- Five stocks we like better than Avid Bioservices
- What Are Dividend Champions? How to Invest in the Champions
- Penny Stock SurgePays Rises 70%: 1 Reason to Buy, 5 to SellĀ
- Health Care Stocks Explained: Why You Might Want to Invest
- Top 3 Beverage Stocks Pouring Out Profits
- What Investors Need to Know to Beat the Market
- CarMax and Carvana: Steering the Used Car Market
Receive News & Ratings for Avid Bioservices Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avid Bioservices and related companies with MarketBeat.com's FREE daily email newsletter.